Skip to main content
. 2024 May 31;44(Suppl 1):182–197. doi: 10.7705/biomedica.6951

Table 3. A bivariate analysis evaluating the association between the sociodemographic and clinical variables with short-term all-cause mortality in patients with type 2 diabetes mellitus diagnosis of the Registro Colombiano de Insuficiencia Cardíaca (RECOLFACA).

Alive (n = 565) n (%) Dead (n =55) n (%) Total (N = 620) n (%) p value
Sex
Female 250 (44.25) 27 (49.09) 277 (44.68) 0.490
Male 315 (55.75) 28 (50.91) 343 (55.32)
Age (years) 69 (62.77) 69 (63.79) 69 (62.77) 0.453
Race
Asian 1 (0.18) 0 (0) 1 (0.16)
White 29 (5.13) 2 (3.64) 31 (5)
Indigenous 1 (0.18) 0 (0) 1 (0.16) 0.167
Hispanic 420 (74.34) 35 (63.64) 455 (73.39)
Mestiza 102 (18.05) 14 (25.45) 116 (18.71)
African-American 12 (2.12) 4 (7.27) 16 (2.58)
Hypertension 478 (84.60) 50 (90.91) 528 (85.16) 0.209
Current alcoholism 14 (2.48) 3 (5.45) 17 (2.74) 0.197
Cancer 21 (3.72) 5 (9.09) 26 (4.19) 0.058
Coronary disease 200 (35.40) 24 (43.64) 224 (36.13) 0.225
COPD 99 (17.52) 14 (25.45) 113 (18.23) 0.146
Atrial fibrillation 92 (16.28) 12 (21.82) 104 (16.77) 0.294
Thyroid disease 96 (16.99) 13 (23.64) 109 (17.58) 0.216
Chronic kidney disease 153 (27.08) 24 (43.64) 177 (28.55) 0.009
Valvular disease 80 (14.16) 7 (12.73) 87 (14.03) 0.770
Smoking habits (former or current) 96 (16.99) 16 (29.09) 112 (18.06) 0.026
CABG 57 (10.09) 4 (7.27) 61 (9.84) 0.503
Dyslipidemia 206 (36.46) 14 (25.45) 220 (35.48) 0.103
Chagas disease 11 (1.95) 1 (1.82) 12 (1.94) 0.947
NYHA
I 54 (9.56) 3 (5.45) 57 (9.19)
II 325 (57.52) 27 (49.09) 352 (56.77) 0.167
III 162 (28.67) 20 (36.36) 182 (29.35)
IV 24 (4.25) 5 (9.09) 29 (4.68)
ACC/AHA classification
C 533 (94.34) 52 (94.55) 585 (94.35) 0.949
D 32 (5.66) 3 (5.45) 35 (5.65)
Triple therapy 242 (42.83) 24 (43.64) 266 (42.90) 0.908
Diuretics 391 (69.20) 45 (81.82) 436 (70.32) 0.051
Digoxin 40 (7.08) 5 (9.09) 45 (7.26) 0.583
Nitrates 24 (4.25) 5 (9.09) 29 (4.68) 0.104
Antiplatelet 328 (58.05) 28 (50.91) 356 (57.42) 0.306
Statins 380 (67.26) 27 (49.09) 407 (65.65) 0.007
Anticoagulants 117 (20.71) 20 (36.36) 137 (22.10) 0.008
Pacemaker 0.054
Dual-chamber 24 (4.25) 1 (1.81) 25 (4.42)
Single-chamber 9 (1.59) 3 (5.45) 12 (2.12)
Other implantable devices 0.181
ICD 94 (16.64) 12 (21.82) 106 (17.10)
Resynchronization therapy 10 (1.77) 3 (5.45) 13 (2.10)
ICD + resynchronization therapy 27 (4.78) 2 (3.62) 29 (4.68)
Sinusal rhythm 213 (68.93) 18 (72) 231 (69.16) 0.749
Prolonged QRS complex 126 (40.78) 8 (32) 134 (40.12) 0.389
LV diastolic diameter 55 (48.63) 50.5 (3958) 55 (4863) 0.015
LVEF 34 (25.43) 28 (2040) 33 (2542) 0.101
Anemia 212 (48.51) 20 (46.51) 232 (48.33) 0.007
Serum creatinine 1.2 (0.93-1.60) 1.29 (1.1.8) 1.2 (0.95-1.61) 0.409
GFR (ml/min/1,73 m3) 53.35 (36.05-75.24) 52.37 (33.05-66.58) 53.3 (35.71-74.21) 0.521
Hyponatremia 61 (14.59) 9 (21.43) 70 (15.22) 0.240
Hyperkalemia 54 (11.82) 9 (20.45) 63 (12.57) 0.099
NT-proBNP 2790 (1099-5896) 9496 (996- 1671) 2795 (1002-6857) 0.254

COPD: Chronic obstructive pulmonary disease; CABG: Coronary artery bypass grafting; NYHA: New York Heart Association; ACC/AHA: American College of Cardiology/American Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blockers; ARNI: Angiotensin receptor-neprilysin Inhibitor; MRA: Mineralocorticoid receptor antagonist; ICD: Implantable cardioverter defibrillator; LV: Left ventricle; LVEF: Left ventricular ejection fraction; GFR: Glomerular filtration rate; NT-proBNP: N-terminal pro b-type natriuretic peptide